Technology Office Says Prostate Cancer Screening Not Proven to Save Lives

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 4 No 8
Volume 4
Issue 8

WASHINGTON--A report released by the Congressional Office of Technology Assessment (OTA) says that screening for prostate cancer has not yet been proven to save lives. The report concluded: "Because scientific knowledge is limited, but the consequences of prostate cancer and its treatment are serious, an informed and reasonable patient could equally well decide to have screening or forego it." Nevertheless, OTA said that it would be reasonable for Medicare to consider reimbursement for such screening.

WASHINGTON--A report released by the Congressional Office of TechnologyAssessment (OTA) says that screening for prostate cancer has notyet been proven to save lives. The report concluded: "Becausescientific knowledge is limited, but the consequences of prostatecancer and its treatment are serious, an informed and reasonablepatient could equally well decide to have screening or foregoit." Nevertheless, OTA said that it would be reasonable forMedicare to consider reimbursement for such screening.

Articles in this issue
Physicians Take Aim at Localized Prostate Cancer Treatment Controversy in 'Shootout'
CA 125 Predicts Response to Chemo in Ovarian Ca
Biochemical Modulation Promising in RT-Resistant GI Cancer
Cancer Institute of NJ Adds to its Staff
A Century of Breast Cancer Litigation Is 'Deconstructed'
New Depot Formulation of LHRH Analogue Allows 12-Week Dosing
NSABP Investigation Threatens Academic Freedom for All: Fisher
Cancer Fax Directory in 3rd Edition
HIV-Related Malignancies Increasing, Physicians Tell Panel
Breast Cancer Risk Factors Remain Elusive Target
Conference Celebrates 100 Years of Radiology
Coalition Promotes Worksite Cancer Screening
Search for Ovarian Cancer Screen Must Look Beyond Ultrasound
DNA Defects Predict Endometrial Ca Prognosis
Cost Studies Help Determine Best BMT Use
Related Videos
Robust genetic testing guidelines in the prostate cancer space must be supported by strong clinical research before they can be properly implemented, says William J. Catalona, MD.
Financial constraints and a lack of education among some patients and providers must be addressed to improve the real-world use of certain prostate cancer therapies, says Neeraj Agarwal, MD.
Novel anti-PSMA monoclonal antibody rosopatamab is capable of carrying a bigger payload of radiation particles, which may potentially reduce doses for patients with prostate cancer, says Neeraj Agarwal, MD.
Findings from recent studies support the use of artificial intelligence-based tools in the context of radiation therapy for patients with localized prostate cancer, according to Neeraj Agarwal, MD.
Germline testing may elucidate important mutations in patients with metastatic prostate cancer who may be eligible to receive treatment with PARP inhibitors, according to Neeraj Agarwal, MD.
In this September edition of Snap Recap, we share our highlights from Prostate Cancer Awareness Month, news in the breast cancer space, and the latest FDA updates.
Artificial intelligence programs may help introduce new care strategies that minimize the risk of adverse effects in patients with prostate cancer, according to Wayne G. Brisbane, MD.
An artificial intelligence algorithm appears to create accurate focal treatment margins in patients with prostate cancer, according to Wayne G. Brisbane, MD.
Artificial intelligence may be useful in screening for prostate cancer in patients with elevated prostate specific antigen levels who have undergone MRI, according to Wayne G. Brisbane, MD.
Alicia K. Morgans, MD, MPH, from Dana-Farber Cancer Institute indicates that patients with non-metastatic castration-resistant prostate cancer are able to stay on treatment for long periods of time with darolutamide vs enzalutamide and apalutamide.
Related Content
Olaparib Combo Does Not Yield Significant OS Benefit Vs Placebo in mCRPC | Image Credit: © Dr_Microbe - stock.adobe.com.

Olaparib Combo Does Not Yield Significant OS Benefit Vs Placebo in mCRPC

November 12th 2023
Article

Radiographic progression-free survival outcomes with olaparib plus abiraterone acetate and prednisone appear to be consistent with prior analyses of the phase 3 PROpel trial.

Oncology Peer Review On-The-Go: Successful Diagnosis and Treatment of Occult Prostate Cancer Despite Multiple Negative Prostate Biopsies and Negative Prostate MRIs

Oncology Peer Review On-The-Go: Successful Diagnosis and Treatment of Occult Prostate Cancer Despite Multiple Negative Prostate Biopsies and Negative Prostate MRIs

May 30th 2022
Podcast

Judd W. Moul, MD, spoke with CancerNetwork® about the latest research from the journal ONCOLOGY® on the treatment of a patients with evidence of prostate cancer despite multiple negative prognostic tests.

Results from a phase 1 of study of 177Lu-PSMA-617 in combination with pembrolizumab show significant anti-tumor activity with low toxicity in patients with metastatic castration-resistant prostate cancer.

Pembrolizumab/177Lu-PSMA-617 May Be a New Treatment for Patients with mCRPC

November 1st 2023
Article

Results from a phase 1 of study of 177Lu-PSMA-617 in combination with pembrolizumab show significant anti-tumor activity with low toxicity in patients with metastatic castration-resistant prostate cancer.

Oncology Peer Review On-The-Go: Efficacy of PARP Inhibitors as Maintenance Therapy for Metastatic Castration-Resistant Prostate Cancer

Oncology Peer Review On-The-Go: Efficacy of PARP Inhibitors as Maintenance Therapy for Metastatic Castration-Resistant Prostate Cancer

April 26th 2022
Podcast

Muhammad Rafay Khan Niazi, MD, and Alexander Bershadskiy, MD, spoke with CancerNetwork® about the latest research from the journal ONCOLOGY® on the use of PARP inhibitors as maintenance therapy for certain patients with metastatic castration-resistant prostate cancer.

Investigators will assess the safety and preliminary anti-tumor activity of ONCT-534 in metastatic castration-resistant prostate cancer in the phase 1/2 study ONCT-534-101.

ONCT-534 Earns FDA Fast Track Designation in R/R Metastatic CRPC

October 27th 2023
Article

Investigators will assess the safety and preliminary anti-tumor activity of ONCT-534 in metastatic castration-resistant prostate cancer in the phase 1/2 study ONCT-534-101.

The Canadian approval of relugolix for advanced prostate cancer is based on findings from the phase 3 HERO study.

Canadian Authorities Approve Relugolix for Advanced Prostate Cancer

October 25th 2023
Article

The Canadian approval of relugolix for advanced prostate cancer is based on findings from the phase 3 HERO study.